(Q35898395)

English

The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.

scientific article published on 19 January 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26786874%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26786874%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

dasatinib monohydrate

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Percy A. Knolle

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26786874%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Annkristin Heine

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26786874%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Judith Schilling

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26786874%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Barbara Grünwald

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26786874%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Achim Krüger

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26786874%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Heidrun Gevensleben

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26786874%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Stefanie Andrea Erika Held

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26786874%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Natalio Garbi

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26786874%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Christian Kurts

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26786874%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Peter Brossart

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26786874%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Linda Diehl

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26786874%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Bastian Höchst

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26786874%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

19 January 2016

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26786874%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26786874%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

65

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26786874%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26786874%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

273-282

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26786874%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

https://scigraph.springernature.com/pub.10.1007/s00262-015-1790-5

0 references

Myeloid-derived suppressor cells as therapeutic target in hematological malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Myeloid derived suppressor cells in human diseases

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Myeloid-derived cells are key targets of tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Tumor escape mechanism governed by myeloid-derived suppressor cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Myeloid-derived suppressor cells in human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Myeloid-derived suppressor cell heterogeneity in human cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Myeloid-derived suppressor cells as regulators of the immune system

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Myeloid-derived suppressor cell heterogeneity and subset definition.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Advances in immunotherapy of chronic myeloid leukemia CML.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Targeting immune suppressing myeloid-derived suppressor cells in oncology.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

The role of the p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, and phosphoinositide-3-OH kinase signal transduction pathways in CD40 ligand-induced dendritic cell activation and expansion of virus-specific CD8+ T cell m

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Immunomodulatory effects of anti-angiogenic drugs

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1790-5

21 January 2018

Identifiers

10.1007/S00262-015-1790-5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26786874%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

release_ouvctfn2d5ds5cvab5wt2gngsq

1 reference

https://api.fatcat.wiki/v0/release/ouvctfn2d5ds5cvab5wt2gngsq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26786874%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35898395&oldid=1844507533"